French drugmaker Sanofi (Euronext: SAN) is presenting clinical data from its insulin portfolio at the 2019 congress of the International Diabetes Federation (IDF), in Busan, South Korea.
The firm is offering details from a new comparison of gastrointestinal adverse events with a GLP-1 receptor agonist and Soliqua (insulin glargine/lixisenatide), a combination therapy containing both a long-acting human insulin analog and a GLP-1 receptor agonist.
In a separate presentation, a post-hoc sub-analysis of the BRIGHT study of Toujeo (insulin glargine) will also be unveiled, showing outcomes for Toujeo versus insulin degludec in older adults with type 2 diabetes.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze